Optimal antiproteinuric dose of losartan in nondiabetic patients with nephrotic range proteinuria

This publication has 15 references indexed in Scilit:

• Chronic proteinuric nephropathies: Outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury
  American Journal of Kidney Diseases, 2000
• Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies
  Kidney International, 1998
• Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
  The Lancet, 1997
• Effect of the Angiotensin-Converting–Enzyme Inhibitor Benazepril on the Progression of Chronic Renal Insufficiency
  New England Journal of Medicine, 1996
• Proteinuria and blood pressure as causal components of progression to end-stage renal failure
  Nephrology Dialysis Transplantation, 1996
• Blood Pressure Control, Proteinuria, and the Progression of Renal Disease
  Annals of Internal Medicine, 1995
• The Effect of Angiotensin-Converting-Enzyme Inhibition on Diabetic Nephropathy
  New England Journal of Medicine, 1993
• Long-Term Benefits of the Antiproteinuric Effect of Angiotensin-Converting Enzyme Inhibition in Nondiabetic Renal Disease
  American Journal of Kidney Diseases, 1993
• EARLY AGGRESSIVE ANTIHYPERTENSIVE TREATMENT REDUCES RATE OF DECLINE IN KIDNEY FUNCTION IN DIABETIC NEPHROPATHY
  The Lancet, 1983
• Long-term antihypertensive treatment inhibiting progression of diabetic nephropathy
  BMJ, 1982